Veralox Therapeutics: Funding, Investors & Team (Sep 2026)
Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.
Veralox Therapeutics has raised $40.6M across 2 funding rounds on record, the most recent an undisclosed round of $24.0M announced in Jun 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Veralox Therapeutics Company Profile and Key Stats
Latest funding round on record: Jun 2023.
Veralox Therapeutics Funding Rounds
Veralox Therapeutics raised $16.6M in an undisclosed round announced in Jun 2021.
2 years later, an undisclosed round of $24.0M was announced in Jun 2023.
Veralox Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Veralox Therapeutics Funding Compared to Other Biotechnology Startups
Veralox Therapeutics' latest round of $24.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Veralox Therapeutics in Biotechnology and Frederick
Companies Similar to Veralox Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Veralox Therapeutics Funding FAQs
What does Veralox Therapeutics do?
Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.
How much funding has Veralox Therapeutics raised?
Veralox Therapeutics has raised $40.6M across 2 rounds on record. The most recent is an undisclosed round of $24.0M announced in Jun 2023.
When did Veralox Therapeutics last raise funding?
Veralox Therapeutics' most recent funding round on record is an undisclosed round of $24.0M, announced in Jun 2023.
Who founded Veralox Therapeutics?
FundedIQ lists David J Maloney (Founder) at Veralox Therapeutics.
Who is the CEO of Veralox Therapeutics?
Jeffrey Strovel is listed as CEO at Veralox Therapeutics.
Where is Veralox Therapeutics headquartered?
Veralox Therapeutics is based in Frederick, Maryland, United States.
How many employees does Veralox Therapeutics have?
Veralox Therapeutics is in the 1-10 employee band.
How does Veralox Therapeutics' funding compare to other Biotechnology startups?
Veralox Therapeutics' latest round of $24.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Veralox Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Veralox Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.